Edition:
United States

Celsion Corp (CLSN.O)

CLSN.O on Consolidated Issue listed on NASDAQ Capital Market

0.64USD
8 Dec 2016
Change (% chg)

$-0.04 (-5.63%)
Prev Close
$0.68
Open
$0.68
Day's High
$0.68
Day's Low
$0.64
Volume
128,483
Avg. Vol
108,016
52-wk High
$2.05
52-wk Low
$0.62

CLSN.O

Chart for CLSN.O

About

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall... (more)

Overall

Beta: 1.67
Market Cap(Mil.): $17.73
Shares Outstanding(Mil.): 26.08
Dividend: --
Yield (%): --

Financials

  CLSN.O Industry Sector
P/E (TTM): -- 41.20 30.65
EPS (TTM): -0.90 -- --
ROI: -60.80 -0.59 15.23
ROE: -124.36 -1.31 16.56

BRIEF-Celsion provides update on immunotherapy study in ovarian cancer patients

* Celsion announces continuing positive data from the ovation study - an immunotherapy study of newly diagnosed stage iii and iv ovarian cancer patients

Nov 10 2016

BRIEF-Celsion Corp reports Q3 loss per share $0.23

* Celsion corporation reports third quarter 2016 financial results and provides business update

Nov 10 2016

BRIEF-Celsion files for resale of up to 8.8 mln shares of co's common stock

* Files for resale of up to 8.8 million shares of co's common stock by selling stockholders - SEC filing Source text for Eikon: [http://bit.ly/2dWdFbl] Further company coverage:

Oct 31 2016

BRIEF-Celsion corp gets positive DSMB review of Phase Ib ovation study

* Says future studies of GEN-1 will include a phase I/II study combining GEN-1 with avastin and doxil

Sep 15 2016

BRIEF-Zhejiang Hisun Pharma signs agreement with U.S.-based Celsion Corp

* Says it signs agreement on technology transfer, production and products supply with Celsion Corp

Aug 16 2016

BRIEF-Celsion posts Q2 loss of $0.19/share

* Celsion Corporation reports second quarter 2016 financial results and provides business update

Aug 15 2016

BRIEF-Celsion announces final overall survival data from HEAT study of ThermoDox in primary liver cancer

* Median overall survival for ThermoDox group reached which translates into two year survival benefit over optimized RFA only group

Aug 15 2016

BRIEF-Celsion Co, Zhejiang Hisun Pharma sign deal for development of GEN-1 immuno-oncology therapy

* Co, Zhejiang Hisun Pharma sign technology transfer, manufacturing and commercial supply deal for development of GEN-1 immuno-oncology therapy

Aug 09 2016

BRIEF-Celsion Corp says updates on OVATION study

* Celsion Corp says announces positive data from OVATION study Source text for Eikon: Further company coverage:

Jul 25 2016

BRIEF-Celsion Corp announces $6 mln registered direct offering

* Celsion corporation announces $6 million registered direct offering

Jun 13 2016

Earnings vs. Estimates